#South Korea #Seoul #Heart Failure #Sky Labs #CART Monitor

Introduction to CART Blood Pressure Monitor

In recent years, advancements in wearable technology have made significant strides in the healthcare industry. Sky Labs, led by CEO Jack ByungHwan Lee, recently unveiled the impressive capabilities of its ring-type blood pressure monitor, named CART, during the ESC Congress 2026 held in Munich, Germany. This innovative device has caught considerable attention, especially for its applications in monitoring patients with atrial fibrillation (AF) and heart failure (HF).

Clinical Findings Presented at ESC 2026

On September 7, 2026, Sky Labs presented groundbreaking clinical research findings on the CART blood pressure monitor. The sessions focused specifically on its utility for AF and HF patients, showcasing new data that promises to change how clinicians monitor these populations. The company hosted five dedicated sessions discussing the research, further highlighting its dedication to advancing cardiovascular care.

Effectiveness in Monitoring Atrial Fibrillation

Professor Ki-Hong Lee from Chonnam National University Hospital presented a compelling study regarding 24-hour blood pressure monitoring in patients with AF. They reported an impressive analyzable data rate of about 80%, affirming the CART monitor’s effectiveness in providing continuous observation of nocturnal dipping patterns. This ability is particularly crucial for monitoring AF, which often brings challenges in maintaining accurate blood pressure readings due to irregular heart rhythms.

Success in Heart Failure Applications

Further, research shared by Professor In-Cheol Kim of Keimyung University Dongsan Hospital revealed that CART has shown great promise in managing severe heart failure cases. This study involved a simultaneous comparison of the CART monitor against traditional 24-hour ambulatory blood pressure monitoring (ABPM) methods. Remarkably, results indicated high agreement between both devices, satisfying the European Society of Hypertension (ESH) error margin criteria and solidifying CART's position as a reliable tool in personalized heart failure treatment plans.

Overcoming Measurement Barriers

CART’s unique design enables continuous blood pressure tracking in patients who historically faced significant challenges with conventional cuff options, mainly due to irregular pulses and high variability. The device’s capabilities facilitate more effective monitoring, allowing healthcare professionals to tailor treatments more optimally based on accurate data.

Supporting Clinical Findings

Several other key findings were shared at ESC 2026. Professor Hae-Young Lee emphasized the device's reliability, confirming its compliance with ESH recommendations for cuffless devices through extensive testing across various scenarios.

Professor Eun-Mi Lee illustrated a real-world case where CART successfully reduced unnecessary medication in a patient suffering cuff-induced discomfort, showcasing how the technology can enhance patient experiences while driving meaningful care improvements. Further support came from Professor Jong-Chan Youn, who examined over 12,000 events related to sleep-related breathing disorders in 62 patients suffering from sleep apnea. Notably, he recorded significant blood pressure surges immediately following the resumption of breathing, highlighting CART's relevance in diverse patient populations.

Industry Recognition and Future Outlook

Amid these impressive clinical validations, notable industry figures such as Professors Seok-Min Kang and George Stergiou commended Sky Labs for adhering strictly to the rigorous ESH criteria specifically for cuffless devices, a feat that positions the company favorably in the realm of cardiovascular monitoring technology.

The CART blood pressure monitor operates using advanced photoplethysmography (PPG) sensors combined with artificial intelligence, enabling 24-hour cuffless measurements through a discreet finger ring design. Since its inception, it has gained traction, being actively prescribed in over 2,000 medical institutions across Korea, accumulating over 300,000 prescriptions. Its listing in the 2026 Korean Society of Hypertension Guidelines as the first-ever ring-type cuffless monitor adds further credibility to its clinical applications.

Jack ByungHwan Lee stated, "Our presentations at ESC 2026 reaffirmed CART’s significant potential in managing complex cardiovascular cases such as AF and HF. With over 300,000 prescriptions backing us and our inclusion in established guidelines, we’re looking to expedite our venture into both the European and global markets."

Conclusion

Sky Labs’ CART blood pressure monitor epitomizes the future of remote and efficient cardiovascular care, specifically catering to populations previously challenged by traditional measurement techniques. As more healthcare providers and patients recognize its transformative potential, the implications for better individual health outcomes in AF and HF management are profound.

• ---

For more on Sky Labs and CART, please visit Sky Labs Official Site.

_Disclaimer: The CART blood pressure monitor is available only by prescription and should be used under the direction of a healthcare professional. Adjustments to medications should always be made in consultation with qualified healthcare providers._